Transcriptional analysis of doxorubicin-induced cardiotoxicity
Open Access
- 1 March 2006
- journal article
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 290 (3), H1098-H1102
- https://doi.org/10.1152/ajpheart.00832.2005
Abstract
Doxorubicin is an effective chemotherapeutic agent against a broad range of tumors. However, a threshold dose of doxorubicin causes an unacceptably high incidence of heart failure and limits its clinical utility. We have established two models of doxorubicin cardiotoxicity in mice: 1) in an acute model, mice are treated with 15 mg/kg of doxorubicin once; and 2) in a chronic model, they receive 3 mg/kg weekly for 12 wk. Using echocardiography, we have monitored left ventricular function during treatment in the chronic model and seen the expected development of dilated cardiomyopathy. Treated mice showed histological abnormalities similar to those seen in patients with doxorubicin cardiomyopathy. To investigate transcriptional regulation in these models, we used a muscle-specific cDNA microarray. We have identified genes that respond to doxorubicin exposure in both models and confirmed these results using real-time PCR. In the acute model, a set of genes is regulated early and rapidly returns to baseline levels, consistent with the half-life of doxorubicin. In the chronic model, which mimics the clinical situation much more closely, we identified dysregulated genes that implicate specific mechanisms of cardiac toxicity. These include STARS, a hypertrophy-responsive gene; SNF1-kinase, a potential modulator of ATP levels; and AXUD1, a downstream target of the proapoptotic regulator AXIN1.Keywords
This publication has 30 references indexed in Scilit:
- STARS, a Striated Muscle Activator of Rho Signaling and Serum Response Factor-dependent TranscriptionJournal of Biological Chemistry, 2002
- Manganese Superoxide Dismutase Transgenic Mice: Characteristics and ImplicationsMethods in enzymology, 2002
- Pharmacokinetic-Pharmacodynamic Relationships of the Anthracycline Anticancer DrugsClinical Pharmacokinetics, 2002
- Metabolic control: A new solution to an old problemCurrent Biology, 2000
- BTG gene expression in the p53-dependent and -independent cellular response to DNA damageMolecular Carcinogenesis, 2000
- AMP-activated protein kinase: an ultrasensitive system for monitoring cellular energy chargeBiochemical Journal, 1999
- Antioxidants protect against reactive oxygen species associated with adriamycin-treated cardiomyocytesCancer Letters, 1999
- Growth Hormone Treatment Prevents the Decrease in Insulin-Like Growth Factor I Gene Expression in Patients Undergoing Abdominal SurgeryJournal of Clinical Endocrinology & Metabolism, 1998
- Magnetic resonance imaging accurately estimates LV mass in a transgenic mouse model of cardiac hypertrophy.American Journal of Physiology-Heart and Circulatory Physiology, 1998
- Apoptosis in cancer therapy: Crossing the thresholdCell, 1994